Earnings
XPENG Revenue Climbs 19% — But Its Net Loss Widens To RMB870 Million
Vehicle margins improved from the second quarter, while XPENG expects fourth-quarter deliveries to grow about 45%–50% from a year earlier.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Vehicle margins improved from the second quarter, while XPENG expects fourth-quarter deliveries to grow about 45%–50% from a year earlier.
SEC Filings
The other named executive officers' agreements will run through December 31, 2028, under an existing extension provision.
Earnings
Customer pricing and Medicare Advantage talks remain unfinished, while the company narrowed its 2026 adjusted earnings outlook.
SEC Filings
Weekly dosing reached 99% suppression, while the ongoing study will measure weight, fat and lean mass at week 24.
SEC Filings
Vir expects approximately $140.4 million after costs, with additional proceeds possible if underwriters exercise their option.
SEC Filings
The company expects about $93.5 million after offering costs as preliminary ersodetug study findings await complete analysis.
SEC Filings
Ivonescimab missed the trial's main survival goal, while Summit plans to keep developing the drug across other cancers.
SEC Filings
The new holding accounted for about 25% of the disclosed portfolio, while Fairfax exited Orla Mining.
Deals
The biotech plans approximately $140 million in purchases through 2028 while funding drug development and selective acquisitions.
SEC Filings
The disclosed US stock portfolio grew to $54.5 billion, while the investment firm reduced its Cerebras stake.
SEC Filings
Overdue domestic card loans totaled $10.1 billion, with uncollectible billed interest and fees reducing revenue separately.
SEC Filings
Shareholders would receive Transocean stock, while Valaris added merger information to limit litigation costs and delay risks.